surpass cvot tirzepatide SURPASS-CVOT trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I 💡 New insight in diabetes

Real-time measurements of dopamine via fiber photometry revealed specific dopamine changes in the nucleus accumbens at both the beginning and end of running bouts, with SG-treated animals showing amplified dopamine dynamics at these key behavioral timepoints

How they work, benefits, possible side effects, and whether this treatment is right for you.

Resmetirom approval and promising incretin-based therapies reshape the treatment landscape for liver and cardiometabolic outcomes.

GLP-1 RA use was consistently associated with improvements in headache frequency, weight reduction, and reduced need for acetazolamide or surgical interventions

"The rollercoaster of my body is a challenging, but beautiful ride."